FDA bans suck sales of Ranbaxy, Wockhardt

FDA bans suck sales of Ranbaxy, Wockhardt The flipside of the problems Ranbaxy was the head of Novartis ($ NVS), which last week was able to increa...


FDA bans suck sales of Ranbaxy, Wockhardt
The flipside of the problems Ranbaxy was the head of Novartis ($ NVS), which last week was able to increase its earnings forecast because Ranbaxy have the problems that it always kept a generic Diovan on the market. The Swiss drugmaker said last week …
Read more at

Leave a Reply